Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: A multicenter phase II trial

Journal of Clinical Oncology

Volumn 16, Issue 8, 1998, Pages 2728-2732

  Ravaud, Alain ^a   Audhuy, Bruno ^a   Gomez, Frédéric ^a   Escudier, Bernard ^a   Lesimple, Thierry ^a   Chevreau, Christine ^a   Douillard, Jean Yves ^a   Caty, Armelle ^a   Geoffrois, Lionel ^a   Ferrero, Jean Marc ^a   Linassier, Claude ^a   Drevon, Michel ^a   Négrier, Sylvie ^a  

^a INSTITUT BERGONIÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; FLUOROURACIL; PARACETAMOL; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERANCE; ERYTHEMA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUTHWASH; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPTIC SHOCK; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0031904556     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.8.2728     Document Type: Article

References (24)

1. Rosenberg SA, Lotze MT, Yang JC, et al: Experience with the use of high dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474-485, 1989
2. West WH, Tauer KW, Yannelli JR, et al: Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898-905, 1987
3. Négrier S, Philip T, Stoter G, et al: Interleukin-2 (IL-2) with or without LAK cells in metastatic renal cell carcinoma: A report of a European multicenter study. Eur J Cancer 25:21-28, 1989 (suppl 3)
4. Quesada JR, Rios A, Swanson DA, et al: Antitumor activity of recombinant-derived interferon α in metastatic renal cell carcinoma. J Clin Oncol 3:1522-1528, 1985
5. Cameron RB, McIntosh JK, Rosenberg SA: Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases. Cancer Res 48:5810-5817, 1988
6. Rosenberg SA, Lotze MT, Yang JC, et al: Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 7:1863-1874, 1989
7. Négrier S, Escudier B, Lasset C, et al: Interleukin-2, interferon or both in 425 patients with metastatic renal cell cancer: Results of a multicenter randomized trial. N Engl J Med 338:1272-1278, 1998
8. Elias L, Sandoval JM: Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun 163:867-874, 1989
9. Pfeffer LM, Tamm I: Interferon inhibition of thymidine incorporation into DNA through effects on thymidine transport and uptake. J Cell Physiol 121:431-436, 1984
10. Seymour MT, Patel N, Johnston A, et al: Lack of effect of interferon alfa-2a in upon fluorouracil pharmacokinetics. Br J Cancer 70:724-728, 1994
11. Grem JL, Mc Atee, Murphy RF, et al: A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. J Clin Oncol 9:1811-1820, 1991
12. Atzpodien J, Kirchner H, Hänninen EL, et al: European studies of interleukin-2 in metastatic renal cell carcinoma. Semin Oncol 20:22-26, 1993 (suppl 9)
13. Hofmockel G, Langer W, Theiss M, et al: Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-α and 5-fluorouracil. J Urol 156:18-21, 1996
14. Ellerhorst JA, Sella A, Amato RJ, et al: Phase II trial of 5-fluorouracil, interferon-α and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer 80:2128-2132, 1997
15. Thiesse P, Ollivier L, Di-Stefano-Louineau D, et al: Response rate accuracy in oncological trial: Reasons for interobserver variability. J Clin Oncol 15:3507-3514, 1997
16. Sleijfer DT, Janssen RAJ, Buter J, et al: Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatients basis. J Clin Oncol 10:1119-1123, 1992
17. Sella A, Logothetis CJ, Fitz K, et al: Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer. J Urol 147:573-577, 1992
18. Ravaud A, Négrier S, Cany L, et al: Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma. Br J Cancer 69:1111-1114, 1994
19. Sella A, Kilbourn RG, Gray I, et al: Phase I study of interleukin-2 combined with interferon-α and 5-fluorouracil in patients with metastatic renal cell cancer. Cancer Biother 9:103-111, 1994
20. Gauny S, Zimmerman RJ, Winkelhake JL: Combination therapies using interleukin-2 and chemotherapeutics in murine tumors. Proc Am Assoc Cancer Res 30:372, 1989 (abstr)
21. Kawano Y, Kubota T, Watanabe M, et al: Synergistic antitumor activity of interleukin-2, mitomycin C and 5-fluorouracil against colon cancer. Proc Am Assoc Cancer Res 35:323, 1994 (abstr)
22. Lee M, Pierce A, Mahaffey W, et al: Interleukin-2 in neoadjuvant therapy potentiates inhibitory activity of 5-fluorouracil, leucovorin and interleukin-2. Anticancer Drugs 5:239-243, 1994
23. Slater LM, Wetzel MW, Cesario T: Combined interferon-antimetabolite therapy of murine L1210 leukemia. Cancer 48:5-9, 1981
24. Brostrom LA: The combined effect of interferon and methotrexate on human osteosarcoma and lymphoma cell lines. Cancer Lett 10:83-90, 1980